Transport, metabolism and elimination mechanisms of anti-HIV agents (Q33933489)

30 July 2017

Transport, metabolism and elimination mechanisms of anti-HIV agents (English)

1 reference

30 July 2017

Li X

1

1 reference

PubMed ID

10837769

30 July 2017

Chan WK

series ordinal

2

1 reference

PubMed ID

10837769

30 July 2017

language of work or name

English

0 references

publication date

1 October 1999

1 reference

Advanced Drug Delivery Reviews

30 July 2017

1 reference

30 July 2017

39

1 reference

30 July 2017

1-3

1 reference

30 July 2017

81-103

1 reference

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

The antigenic structure of the HIV gp120 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Mechanism and site dependency of intestinal mucosal transport and metabolism of thymidine analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Absorption of 2',3'-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Determination intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Oral absorption of anti-aids nucleoside analogues: 3. Regional absorption and in vivo permeability of 2',3'-dideoxyinosine in an intestinal-vascular access port (IVAP) dog model.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Determination of intrinsic membrane transport parameters from perfused intestine experiments: A boundary layer approach to estimating the aqueous and unbiased membrane permeabilities

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Intestinal absorption of dideoxynucleosides: characterization using a multiloop in situ technique

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Nucleoside and nucleobase transport in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Independent blood-brain barrier transport systems for nucleic acid precursors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Nucleoside transport in animal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Nucleoside transporter of cerebral microvessels and choroid plexus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Oral absorption of anti-acquired immune deficiency syndrome nucleoside analogues. 2. Carrier-mediated intestinal transport of stavudine in rat and rabbit preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Enhancement of the in vitro skin permeability of azidothymidine (AZT) via iontophoresis and chemical enhancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Mutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Characterization of the barrier properties of mucosal membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Nasal absorption of 2',3'-didehydro-3'-deoxythymidine (D4T) and its esters in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Direct transport of 2',3'-didehydro-3'-deoxythymidine (D4T) and its ester derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

A study of the permeability barrier in epidermis and oral epithelium using horseradish peroxidase as a tracer in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Membrane coating granules in nonkeratinizing oral epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Transbuccal delivery of acyclovir: I. In vitro determination of routes of buccal transport

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Neuronal injury associated with HIV-1: approaches to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Drug transport in the central nervous system: role of carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Restricted transport of 3'-azido-3'-deoxythymidine and dideoxynucleosides through the blood-brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Efflux of zidovudine and 2',3'-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Mechanism and rate of placental transfer of zalcitabine (2',3'-dideoxycytidine) in Macaca nemestrina

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Transfer of dideoxyinosine across the human isolated placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

The maternal-fetal transfer of lamivudine in the ex vivo human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Zidovudine does not affect transplacental transfer or systemic clearance of stavudine (2',3'-didehydro-3'-deoxythymidine) in the pigtailed macaque (Macaca nemestrina)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

3'-azido-3'-deoxythymidine and acyclovir: antiviral nucleoside analogues with unusual cell membrane permeation properties

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

2',3'-Dideoxythymidine permeation of the human erythrocyte membrane by nonfacilitated diffusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Membrane permeation mechanisms of 2',3'-dideoxynucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Permeation and metabolism of anti-HIV and endogenous nucleosides in human immune effector cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Comparison of uptake characteristics of thymidine and zidovudine in a human intestinal epithelial model system

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Cross-resistance to anti-HIV nucleoside analogs in multidrug-resistant human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Cellular phosphorylation of anti-HIV nucleosides. Role of nucleoside diphosphate kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

X-ray analysis of azido-thymidine diphosphate binding to nucleoside diphosphate kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Clinical pharmacokinetics of nucleoside antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Reversal of the cytotoxicity of 3'-amino-3'-deoxythymidine by pyrimidine deoxyribonucleosides

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Effect of 3'-amino-3'-deoxythymidine on L1210 and P388 leukemias in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3'-azido-3'-deoxythymidine (AZT) to 3'-amino-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Intracellular metabolism of 3'-azido-3'-deoxythymidine (AZT): a nuclear magnetic resonance study on T-lymphoblastoid cell lines with different resistance to AZT.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Tissue disposition of zidovudine and its phosphorylated metabolites in zidovudine-treated healthy and retrovirus infected mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Comparative pharmacokinetics of antiviral nucleoside analogues

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacodynamics of 2′,3′-dideoxycytidine: An inhibitor of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Cellular metabolism of (−) enantiomeric 2′-deoxy-3′-thiacytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics of nevirapine: initial single-rising-dose study in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

1 reference

7 January 2021

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Nelfinavir. A review of its therapeutic efficacy in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Disposition of intravenous and oral cyclosporine after administration with grapefruit juice

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Interaction of citrus juices with felodipine and nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Interaction between grapefruit juice and diazepam in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Interaction between grapefruit juice and midazolam in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

The pharmacokinetics of combination therapy with nelfinavir plus nevirapine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Lack of pharmacokinetic interaction between nelfinavir and nevirapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Percutaneous absorption of 2',3'-dideoxyinosine in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Enhanced transdermal delivery of zidovudine in rats and human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Enhanced delivery of zidovudine through rat and human skin via ester prodrugs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Extensive absorption of 2',3'-dideoxyinosine by intratracheal administration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Intestinal absorption and first-pass elimination of 2', 3'-dideoxynucleosides following oral administration in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Prodrugs of 2',3'-dideoxyinosine (DDI): improved oral bioavailability via hydrophobic esters

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Synthesis and structure-activity relationships of 6-substituted 2',3'-dideoxypurine nucleosides as potential anti-human immunodeficiency virus agents

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Improved brain delivery of AZT using a glycosyl phosphotriester prodrug.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Evaluation of a brain-targeting zidovudine chemical delivery system in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3'-azido-2',3'-dideoxyuridine and 3'-azido-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2',3'-dideoxyinosine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Lymphoid tissues targeting of liposome-encapsulated 2',3'-dideoxyinosine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Synthesis and evaluation of 5′ alkyl ester prodrugs of zidovudine for directed lymphatic delivery

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Ester prodrugs of zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Synthesis and biological evaluation of prodrugs of zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Prodrugs of 2',3'-didehydro-3'-deoxythymidine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Prodrugs of 2',3'-didehydro-3'-deoxythymidine (D4T): synthesis, antiviral activity, and rapid pharmacokinetic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Preparation and evaluation of sustained release AZT-loaded microspheres: optimization of the release characteristics using response surface methodology.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Human red blood cells as bioreactors for the release of 2',3'-dideoxycytidine, an inhibitor of HIV infectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

Saquinavir. Clinical pharmacology and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

1 reference

7 January 2021

Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0169-409X%2899%2900021-6

7 January 2021

10.1016/S0169-409X(99)00021-6

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10837769